文献速递胸部肿瘤放疗放疗物理与技术

度伐利尤单抗时代不可切除或III期非小细胞肺癌中免疫细胞辐射剂量的影响

Impact of radiation dose to the immune cells in unresectable or stage III non-small cell lung cancer in the durvalumab era.
PubMed 文献 · Radiother Oncol · 2022-07-20

该单机构多中心研究纳入100例不可切除II/III期非小细胞肺癌患者,接受放化疗后度伐利尤单抗治疗,评估免疫细胞估计辐射剂量(EDIC)的预后影响。EDIC>6 Gy组总生存期更短(29.6个月 vs 未达到;p<0.001),多因素分析显示EDIC>6 Gy与更差的总生存期(HR 4.15)、无进展生存期(HR 3.79)和局部区域控制(HR 2.66)相关。结论认为在免疫治疗时代,EDIC是局部晚期非小细胞肺癌总生存期和疾病控制的独立预测因子,值得研究降低免疫区辐射剂量的技术。

要点

  • EDIC>6 Gy组中IIIB/IIIC期比例更高(76.0% vs 32.6%;p<0.001),肿瘤体积更大(170 cc vs 42 cc;p<0.001)。
  • EDIC>6 Gy组中位总生存期更短(29.6个月 vs 未达到;p<0.001)。
  • 多因素分析显示EDIC>6 Gy与更差的总生存期(HR 4.15)、无进展生存期(HR 3.79)和局部区域控制(HR 2.66)相关。

核心结论

  • 在免疫治疗时代,EDIC是局部晚期非小细胞肺癌总生存期和疾病控制的独立预测因子,值得研究降低免疫区辐射剂量的技术。

研究设计与样本

  • 单机构多中心研究,纳入100例不可切除II/III期非小细胞肺癌患者,接受放化疗后度伐利尤单抗治疗,中位随访23.7个月。

主要发现

  • EDIC>6 Gy组中IIIB/IIIC期比例更高(76.0% vs 32.6%;p<0.001),肿瘤体积更大(170 cc vs 42 cc;p<0.001)。
  • EDIC>6 Gy组因毒性早期停用度伐利尤单抗的比例与≤6 Gy组无差异(24.1% vs 15.2%;p=0.27)。
  • EDIC>6 Gy组中位总生存期更短(29.6个月 vs 未达到;p<0.001)。
  • 多因素分析显示EDIC>6 Gy与更差的总生存期(HR 4.15,95%CI 1.52-11.33;p=0.006)、无进展生存期(HR 3.79,95%CI 1.80-8.0;p<0.001)和局部区域控制(HR 2.66,95%CI 1.15-6.18;p=0.023)相关。
  • 作为连续变量分析,较高的EDIC与更差的总生存期(HR 1.34,95%CI 1.16-1.57;p<0.001)、无进展生存期(HR 1.52,95%CI 1.29-1.79;p<0.001)和局部区域控制(HR 1.34,95%CI 1.13-1.60;p=0.007)相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/PURPOSE: Higher estimated radiation doses to immune cells (EDIC) have correlated with worse overall survival (OS) in patients with locally-advanced non-small cell lung cancer (NSCLC) prior to the PACIFIC trial, which established consolidative durvalumab as standard-of-care. Here, we examine the prognostic impact of EDIC in the durvalumab era. MATERIALS/METHODS: This single-institution, multi-center study included patients with unresectable stage II/III NSCLC treated with chemoradiation followed by durvalumab. Associations between EDIC [analyzed continuously and categorically (≤6 Gy vs > 6 Gy)] and OS, progression-free survival (PFS), and locoregional control (LRC) were evaluated by Kaplan-Meier and Cox proportional methods. RESULTS: 100 patients were included with median follow-up of 23.7 months. The EDIC > 6 Gy group had a significantly greater percentage of stage IIIB/IIIC disease (76.0 % vs 32.6 %; p < 0.001) and larger tumor volumes (170 cc vs 42 cc; p < 0.001). There were no differences in early durvalumab discontinuation from toxicity (24.1 % vs 15.2 %; p = 0.27). Median OS was shorter among the EDIC > 6 Gy group (29.6 months vs not reached; p < 0.001). On multivariate analysis, EDIC > 6 Gy correlated with worse OS (HR: 4.15, 95 %CI: 1.52-11.33; p = 0.006), PFS (HR: 3.79; 95 %CI: 1.80-8.0; p < 0.001), and LRC (HR: 2.66, 95 %CI: 1.15-6.18; p = 0.023). Analyzed as a continuous variable, higher EDIC was associated with worse OS (HR: 1.34; 95 %CI: 1.16-1.57; p < 0.001), PFS (HR: 1.52; 95 %CI: 1.29-1.79; p < 0.001), and LRC (HR: 1.34, 95 %CI: 1.13-1.60; p = 0.007). CONCLUSIONS: In the immunotherapy era, EDIC is an independent predictor of OS and disease control in locally advanced NSCLC, warranting investigation into techniques to reduce dose to the immune compartment.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. McCall NS, McGinnis HS, Janopaul-Naylor JR, et al. Impact of radiation dose to the immune cells in unresectable or stage III non-small cell lung cancer in the durvalumab era. Radiother Oncol. 2022. PMID: 35870727. doi:10.1016/j.radonc.2022.07.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。